Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302

被引：0
|
作者：
Mainwaring, P. [1 ]
Yu, E. Y. [2 ]
Londhe, A. [3 ]
Van Poppel, H. [4 ]
Rathkopf, D. E. [5 ,6 ]
Smith, M. R. [7 ,8 ]
Souza, P. [9 ]
Griffin, T. W. [10 ]
Ryan, C. J. [11 ]
机构：
[1] Hematol & Oncol Clin Australia, Brisbane, Qld, Australia
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Janssen Res & Dev LLC, Raritan, NJ USA
[4] Katholieke Univ Leuven Hosp, Louvain, Belgium
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Harvard Univ, Sch Med, Boston, MA USA
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
[9] Univ Western Sydney, Sch Med, Sydney, NSW, Australia
[10] Janssen Res & Dev, Los Angeles, CA USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
BJU INTERNATIONAL | 2014年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
41
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [1] Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302
    Yu, Evan Y.
    Saad, Fred
    Londhe, Anil
    Shore, Neal D.
    Van Poppel, Hendrik
    Rathkopf, Dana E.
    Smith, Matthew R.
    Logothetis, Christopher
    De Souza, Paul L.
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul N.
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott A.
    Small, Eric Jay
    Scher, Howard I.
    Griffin, Thomas W.
    Yu, Margaret K.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Final analysis of the randomised, phase 3, COU-AA-302 study of abiraterone acetate (AA) in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC)
    De Souza, P.
    Smith, M. R.
    Fizazi, K.
    Saad, F.
    Mulders, P. F. A.
    Sternberg, C. N.
    Miller, K.
    Logothetis, C. J.
    Shore, N.
    Small, E. J.
    Carles, J.
    Flaig, T. W.
    Taplin, M-E.
    Higano, C. S.
    De Bono, J. S.
    Griffin, T. W.
    De Porre, P.
    Yu, M. K.
    Park, Y. C.
    Li, J.
    Kheoh, T.
    Naini, V.
    Molina, A.
    Rathkopf, D. E.
    Ryan, C. J.
    BJU INTERNATIONAL, 2015, 115 : 21 - 22
  • [3] IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302
    Saad, Fred
    Kheoh, Thian
    Yu, Margaret K.
    Smith, Matthew R.
    Small, Eric J.
    Mulders, Peter F. A.
    Fizazi, Karim
    Rathkopf, Dana
    Oudard, Stephane
    Scher, Howard I.
    Bellmunt, Joaquim
    Taplin, Mary-Ellen
    Davis, Ian D.
    Schrijvers, Dirk
    Protheroe, Andrew
    Molina, Arturo
    Griffin, Thomas W.
    de Bono, Johann S.
    Ryan, Charles J.
    JOURNAL OF UROLOGY, 2014, 191 (04): : E810 - E810
  • [4] ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC)
    Attard, Gerhardt
    De Bono, Johann Sebastian
    Li, Weimin
    Molina, Arturo
    Griffin, Thomas W.
    Kheoh, Thian San
    Ricci, Deborah Sokol
    Zelinsky, Kathy
    Rathkopf, Dana E.
    Scher, Howard I.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Ryan, Charles J.
    Smith, Matthew Raymond
    De Bono, Johann Sebastian
    Molina, Arturo
    Logothetis, Christopher
    De Souza, Paul L.
    Fizazi, Karim
    Mainwaring, Paul N.
    Piulats Rodriguez, Jose Maria
    Ng, Siobhan
    Carles, Joan
    Mulders, Peter
    San Kheoh, Thian
    Griffin, Thomas W.
    Small, Eric Jay
    Scher, Howard I.
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302
    Oudard, Stephane
    Kheoh, Thian San
    Yu, Margaret K.
    Smith, Matthew R.
    Small, Eric Jay
    Mulders, Peter F. A.
    Fizazi, Karim
    Rathkopf, Dana E.
    Saad, Fred
    Scher, Howard I.
    Bellmunt, Joaquim
    Taplin, Mary-Ellen
    Davis, Ian D.
    Schrijvers, Dirk L.
    Protheroe, Andrew
    Molina, Arturo
    Griffin, Thomas W.
    De Bono, Johann Sebastian
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302
    Ryan, Charles J.
    Londhe, Anil
    Molina, Arturo
    Smith, Matthew R.
    De Bono, Johann Sebastian
    Mulders, Peter
    Rathkopf, Dana E.
    Saad, Fred
    Logothetis, Christopher
    Fizazi, Karim
    Scher, Howard I.
    Small, Eric Jay
    Matheny, Shannon
    Kheoh, Thian San
    Griffin, Thomas W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Shore, Neal
    Rathkopf, Dana
    Smith, Matthew R.
    de Bono, Johann S.
    Logothetis, Christopher
    de Souza, Paul
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott
    Fradet, Yves
    Griffin, Thomas
    Park, Youn C.
    Kheoh, Thian
    Small, Eric J.
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    JOURNAL OF UROLOGY, 2014, 191 (04): : E764 - E764
  • [9] Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
    Wilson, Brooke E.
    Armstrong, Andrew J.
    de Bono, Johann
    Sternberg, Cora N.
    Ryan, Charles J.
    Scher, Howard, I
    Smith, Matthew R.
    Rathkopf, Dana
    Logothetis, Christopher J.
    Chi, Kim N.
    Jones, Robert J.
    Saad, Fred
    De Porre, Peter
    Tran, NamPhuong
    Hu, Peter
    Gillessen, Silke
    Carles, Joan
    Fizazi, Karim
    Joshua, Anthony M.
    EUROPEAN JOURNAL OF CANCER, 2022, 170 : 296 - 304
  • [10] Antitumor activity of taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in study COU-AA-302 for metastatic castration-resistant prostate cancer (mCRPC)
    Ryan, Charles J.
    de Bono, Johann S.
    Smith, Matthew R.
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    Small, Eric J.
    Shore, Neal D.
    Fizazi, Karim
    De Porre, Peter
    Kheoh, Thian
    Li, Jinhui
    Todd, Mary B.
    Griffin, Thomas W.
    Saad, Fred
    BJU INTERNATIONAL, 2015, 116 : 12 - 12
12345